Strain‑Specific Microbial Aging Clocks Drive Neuroinflammation via δ‑Valerobetaine‑Dependent Microglial Priming

Hypothesis: Age‑associated shifts in the gut microbiome create a microbial aging clock that raises circulating δ‑valerobetaine and primes microglial NLRP3 inflammasome activity, linking microbial senescence to cognitive decline.

The gut microbiota of older individuals shows a reproducible increase in Parabacteroides goldsteinii and a loss of butyrate‑producing taxa such as Akkermansia muciniphila ([1][2]). Beyond altered metabolite ratios, we propose that these taxa undergo intrinsic age‑related changes—evidenced by shifts in microbial DNA methylation patterns and reduced replication fidelity—that functionally age the microbial community independent of host chronology. This microbial aging clock elevates production of δ‑valerobetaine, a tryptophan‑derived metabolite known to rise with host age and to suppress hippocampal neurogenesis ([3]).

We further hypothesize that δ‑valerobetaine acts not only as a passive biomarker but as an active signaling molecule that crosses the blood‑brain barrier and engages microglial Toll‑like receptor 4 (TLR4) signaling, leading to NF‑κB‑mediated transcription of NLRP3 and pro‑IL‑1β. Simultaneously, the depletion of butyrate‑producing strains reduces histone deacetylase inhibition in microglia, favoring a hyperacetylated state that sensitizes the NLRP3 inflammasome to δ‑valerobetaine priming. The combined effect is a lowered threshold for inflammasome activation upon secondary stimuli (e.g., ATP or crystalline uric acid), resulting in exaggerated IL‑1β release, synaptic phagocytosis, and impaired long‑term potentiation in the hippocampus.

This mechanistic chain predicts three testable, falsifiable outcomes:

1. Microbial aging clock correlation: Quantifying microbial DNA methylation age in fecal samples will positively correlate with plasma δ‑valerobetaine levels and with microglial NLRP3 protein expression in aged mice; germ‑free mice colonized with aged microbiota will show higher δ‑valerobetaine and microglial priming than those colonized with young microbiota, even when host age is matched.
2. Phage‑targeted rescue: Selective knockdown of P. goldsteinii using host‑specific bacteriophages (≥100‑fold reduction) will decrease plasma δ‑valerobetaine by >40 % and halve microglial NLRP3 activation, restoring spatial memory performance in aged mice to levels comparable with young‑donor FMT recipients ([4]).
3. Engineered butyrate restoration: Colonizing aged mice with a synthetically modified E. coli strain engineered to secrete butyrate and to stably engraft after a single dose will increase hippocampal histone deacetylase activity, reduce NLRP3 inflammasome sensitivity to δ‑valerobetaine, and further improve cognitive scores beyond phage treatment alone ([5]).

If any of these predictions fail—for instance, if phage‑mediated reduction of P. goldsteinii does not lower δ‑valerobetaine or microglial NLRP3 activation, or if engineered butyrate production fails to rescue cognition despite restored metabolite levels—the hypothesis would be falsified, prompting a re‑evaluation of whether microbial aging per se drives neuroinflammation or whether host‑centric mechanisms dominate the gut‑brain axis in aging.